Last updated: 2026-09-07 09:34:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Protara Therapeutics, Inc. (TARA) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $3,94, with a market capitalisation of $232,84M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3,02 to $7,82. This page covers its latest market performance, valuation, price trends and company information.
$232,84M | |
$3,93 | |
$67,08 | |
$1,04 | |
$3,97 | |
179,77K | |
-- | |
-- | |
$7,82 | |
$3,02 | |
-- | |
-- |
Protara Therapeutics, Inc. (TARA) last closed at $3,97 as of 2026-09-04 23:31:00, unchanged from the previous close of $3,97.
During the latest regular trading session, TARA traded between $1,04 and $67,08, with a volume of 179,77K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Protara Therapeutics, Inc. (TARA) moved from $3,79 to $3,94, representing a gain of 3,96% ($0,15).
The stock traded between $3,90 and $3,99 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 308,95 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 19,2%
TARA is currently trading at $3,94, placing it 19,2% of the way from its 52-week low of $3,02 to its 52-week high of $7,82. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 51 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Protara Therapeutics, Inc. (TARA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.